Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ld Market 2027

DelveInsight's 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inflammatory Demyelinating Polyneuropathy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic Inflammatory Demyelinating Polyneuropathy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Disease Understanding


Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction).The disorder sometimes also called as chronic relapsing polyneuropathy. It is characterized by a symmetrical, motor predominant peripheral neuropathy that produces both distal and proximal weakness. Large-fiber abnormalities (weakness and ataxia) predominate, whereas small-fiber abnormalities (autonomic and pain) are less common. The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by diagnosed Prevalent population, gender-specific diagnosed Prevalent population and clinical sub-type specific diagnosed Prevalent population and age- specific diagnosed prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the Prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy was estimated to be 45,127 [7MM] in 2018. United States accounts for the highest CIDP cases, followed by EU5 (Germany, France, Italy, Spain and UK) and Japan. Among the EU5 countries France had the highest Prevalent patient population of Chronic Inflammatory Demyelinating Polyneuropathy, followed by United Kingdom.

Chronic Inflammatory Demyelinating Polyneuropathy Drug Chapters

This segment of the Chronic Inflammatory Demyelinating Polyneuropathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are many disease-modifying treatments for CIDP, but conventional therapies such as corticosteroids, Plasma Exchange (PE), and Intravenous immunoglobulin (IVIg) are considered as the first line therapies. These standard therapies have shown the improvement in 40% to 80% of patients and each of these therapies has been demonstrated to be effective in randomized, double-blind studies. However, a proportion of patients remain refractory to these therapies, individually or in combination. Corticosteroids has been in the therapeutic use for CIDP as of first reporting of cases. Mostly Prednisone and Dexamethasone is indicated among them; which has similar effects between patients with a progressive and relapsing course. Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) is the first and only subcutaneous immunoglobulin (SCIg) approved for the rare disease, and was developed to prevent relapse of neuromuscular disability and impairment, which are two common symptoms of patients with the CIDP condition. Hizentra offers patients a more convenient treatment option with proven efficacy and the flexibility and freedom to self-infuse at home. Detailed chapters for all of the marketed drugs along with other marketed therapies have been covered in the report.

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

The Chronic Inflammatory Demyelinating Polyneuropathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Eventhough the IVIg has the proven efficacy, the therapies are associated with high cost and frequent adverse effects. Current treatments are aimed at modulating the immune response, but as yet there is no clear evidence that these treatments also induce axonal regeneration. As non-responsiveness to treatment seems to be associated with a greater degree of axonal dysfunction, finding therapies aimed at protecting the axon and restoring axonal damage are needed.

According to DelveInsight, the global market of Chronic Inflammatory Demyelinating Polyneuropathy was estimated to be USD 473.5 million in 2018. The United States accounts for the largest market size of Chronic Inflammatory Demyelinating Polyneuropathy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The overall dynamics of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as GGS-CIDP (Teijin Pharma), NewGam (Octapharm) and HyQvia (Shire/Takeda). Out of all these emerging therapies, HyQvia (Shire/Takeda) is expected to have competitive advantage among the upcoming therapies, as it is once a month subcutaneous formulation. This drug is thus expected to have the highest market share, followed by GGS-CIDP (Teijin Pharma) and NewGam (Octapharm).

 

Chronic Inflammatory Demyelinating Polyneuropathy Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Chronic Inflammatory Demyelinating Polyneuropathy Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Chronic Inflammatory Demyelinating Polyneuropathy Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy market.

• Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy market.

• To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy market.

1 Key Insights

2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Overview at a Glance

2.1 Total Market Share (%) Distribution of CIDP in 2017

2.2 Total Market Share (%) Distribution of CIDP in 2027

3 Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview

3.1 Introduction

3.2 Classification

3.3 Clinical Presentation

3.4 CIDP versus Guillain-Barre Syndrome

3.4.1 Disease course

3.5 Disease associations with CIDP

3.6 Pathogenesis oF CIDP

3.7 Diagnosis

3.7.1 Diagnostic criteria

3.7.2 Differential diagnosis

3.7.3 AAN electro diagnostic criteria

3.7.4 Koski et al's criteria

3.7.5 European Federation of Neurological Societies and the Peripheral Nerve Society (EFNS/PNS)

4 Epidemiology and Patient Population

4.1 Key Findings

5 Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM

6 United States Epidemiology

6.1 Assumptions and Rationale

6.2 Total Prevalent Population of CIDP in the United States

6.3 Gender - Specific Prevalent Population of CIDP in the United States

6.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in the United States

6.5 Age - Specific Prevalent Population of CIDP in the United States

7 EU5 Epidemiology

7.1 Germany Epidemiology

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Population of CIDP in Germany

7.1.3 Gender - Specific Prevalent Population of CIDP in Germany

7.1.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in Germany

7.1.5 Age - Specific Prevalent Population of CIDP in Germany

7.2 France Epidemiology

7.2.1 Assumptions and rationale

7.2.2 Total Prevalent Population of CIDP in France

7.2.3 Gender - Specific Prevalent Population of CIDP in France

7.2.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in France

7.2.5 Age - Specific Prevalent Population of CIDP in France

7.3 Italy Epidemiology

7.3.1 Assumptions and Rationale

7.3.2 Total Prevalent Population of CIDP in Italy

7.3.3 Gender - Specific Prevalent Population of CIDP in Italy

7.3.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in Italy

7.3.5 Age - Specific Prevalent Population of CIDP in Italy

7.4 Spain Epidemiology

7.4.1 Assumptions and Rationale

7.4.2 Total Prevalent Population of CIDP in Spain

7.4.3 Gender - Specific Prevalent Population of CIDP in Spain

7.4.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in Spain

7.4.5 Age - Specific Prevalent Population of CIDP in Spain

7.5 United Kingdom Epidemiology

7.5.1 Assumptions and Rationale

7.5.2 Total Prevalent Population of CIDP in the UK

7.5.3 Gender - Specific Prevalent Population of CIDP in the UK

7.5.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in the UK

7.5.5 Age - Specific Prevalent Population of CIDP in the UK

7.6 Japan Epidemiology

7.6.1 Assumptions and Rationale

7.6.2 Total Prevalent Population of CIDP in Japan

7.6.3 Gender - Specific Prevalent Population of CIDP in Japan

7.6.4 Clinical Subtype based Diagnosed Prevalent cases of CIDP in Japan

7.6.5 Age - Specific Prevalent Population of CIDP in Japan

8 Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

8.1 Biological Activity of Available Treatments

8.2 European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of CIDP

8.3 American Academy of Neurology (AAN) - CIDP Evidence based guidelines

8.4 Treatment of CIDP - Cochrane systematic review

9 Treatment Algorithm

10 Unmet Needs

11 Marketed drugs

11.1 Privigen: CSL Behring

11.1.1 Drug Description

11.1.2 Regulatory Milestones

11.1.3 Other Developmental Activities

11.1.4 Safety and Efficacy

11.1.5 Product Profile

11.2 Hizentra: CSL Behring

11.2.1 Product Description

11.2.2 Regulatory Milestones

11.2.3 Other Development Activities

11.2.4 Safety and Efficacy

11.2.5 Product Profile

11.3 Gamunex-C: Grifols/Kiderion Biopharma

11.3.1 Product Description

11.3.2 Regulatory Milestones

11.3.3 Other Development Activities

11.3.4 Safety and Efficacy

11.3.5 Product Profile

11.4 Kenketsu Glovenin-I: Nihon Pharmaceutical

11.4.1 Product Description

11.4.2 Regulatory Milestones

11.4.3 Safety and Efficacy

11.4.4 Product Profile

11.5 Tegeline: LFB

11.5.1 Product Description

11.5.2 Regulatory Milestones

11.5.3 Product Profile

12 Emerging Therapies

12.1 Key Cross Competition

12.2 GGS-CIDP: Teijin Pharma

12.2.1 Drug Description

12.2.2 Other Developmental Activities

12.2.3 Clinical Development

12.2.4 Safety and Efficacy

12.2.5 Product Profile

12.3 Newgam: OctaPharma

12.3.1 Product Description

12.3.2 Clinical Development

12.3.3 Product Profile

12.4 HyQvia: Shire/ Takeda

12.4.1 Product Description

12.4.2 Other Developmental Activities

12.4.3 Clinical Development

12.4.4 Product Profile

12.5 I10E: LFB

12.5.1 Drug Description

12.5.2 Other Developmental Activities

12.5.3 Clinical Development

12.5.4 Product Profile

12.6 MD-1003: MedDay Pharmaceuticals

12.6.1 Drug Description

12.6.2 Other Developmental Activities

12.6.3 Clinical Development

12.6.4 Product Profile

12.7 GNbAC1: GeNeuro Pharmaceuticals

12.7.1 Drug Description

12.7.2 Other Developmental Activities

12.7.3 Clinical Development

12.7.4 Safety and Efficacy

12.7.5 Product Profile

13 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): 7MM Market Analysis

13.1 Key Findings

13.1 Market Size of CIDP in 7MM

14 United States: Market Outlook

14.1 United States Market Size

14.1.1 Total Market size of CIDP

14.1.2 Market Size of CIDP by Emerging therapy in the US

15 EU-5 countries: Market Outlook

15.1 Germany Market Size

15.1.1 Total Market size of CIDP

15.1.2 Market Size of CIDP by Emerging therapy in Germany

15.2 France Market Size

15.2.1 Total Market size of CIDP

15.2.2 Market Size of CIDP by Emerging therapy in France

15.3 Italy Market Size

15.3.1 Total Market size of CIDP

15.3.2 Market Size of CIDP by Emerging therapy in Italy

15.4 Spain Market Size

15.4.1 Total Market size of CIDP

15.4.2 Market Size of CIDP by Emerging therapy in Spain

15.5 United Kingdom Market Size

15.5.1 Total Market size of CIDP

15.5.2 Market Size of CIDP by Emerging therapy in the UK

16 Japan Market Outlook

16.1 Japan Market Size

16.1.1 Total Market size of CIDP

16.1.2 Market Size of CIDP by Emerging therapy in Japan

17 Market Drivers

18 Market Barriers

19 Appendix

19.1 Report Methodology

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

Table 1: Major phenotypic variants of CIDP

Table 2: Clinical subtypes of chronic inflammatory demyelinating polyneuropathy

Table 3: Comparison of CIDP and subtypes

Table 4: Contrast of CIDP and Guillain Barre Syndrome

Table 5: Differential Diagnosis

Table 6: American Academy of Neurology Ad Hoc Subcommittee - electro diagnostic criteria

Table 7: Koski et al's criteria for chronic inflammatory demyelinating polyneuropathy (CIDP)

Table 8: Investigations to be considered

Table 9: EFNS/PNS Diagnostic Criteria for CIDP

Table 10: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the 7MM (2017-2028)

Table 11: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the US (2017-2028)

Table 12: Gender Specific Prevalence of CIDP in the US (2017-2028)

Table 13: Clinical Subtype based Diagnosed Prevalent cases of CIDP in the US (2017-2028)

Table 14: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the US (2017-2028)

Table 15: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2017-2028)

Table 16: Gender Specific Prevalence of CIDP in Germany (2017-2028)

Table 17: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Germany (2017-2028)

Table 18: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2017-2028)

Table 19: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2017-2028)

Table 20: Gender Specific Prevalence of CIDP in France (2017-2028)

Table 21: Clinical Subtype based Diagnosed Prevalent cases of CIDP in France (2017-2028)

Table 22: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France(2017-2028)

Table 23: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2017-2028)

Table 24: Gender Specific Prevalence of CIDP in Italy (2017-2028)

Table 25: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Italy (2017-2028)

Table 26: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2017-2028)

Table 27: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2017-2028)

Table 28: Gender Specific Prevalence of CIDP in Spain (2017-2028)

Table 29: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Spain (2017-2028)

Table 30: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2017-2028)

Table 31: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the UK (2017-2028)

Table 32: Gender Specific Prevalence of CIDP in the UK (2017-2028)

Table 33: Clinical Subtype based Diagnosed Prevalent cases of CIDP in the UK (2017-2028)

Table 34: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the UK (2017-2028)

Table 35: Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2017-2028)

Table 36: Gender Specific Prevalence of CIDP in Japan (2017-2028)

Table 37: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Japan (2017-2028)

Table 38: Age-Specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2017-2028)

Table 39: Recommendations for treatment

Table 40: Evidence classification scheme for a therapeutic intervention

Table 41: Emerging Drugs Analysis

Table 42: GGS-CIDP, Clinical Trial Description, 2019

Table 43: NewGam, Clinical Trial Description, 2019

Table 44: HyQvia, Clinical Trial Description, 2019

Table 45: I10E, Clinical Trial Description, 2019

Table 46: MD-1003, Clinical Trial Description, 2019

Table 47: Market Size of CIDP in 7MM in USD Million (2017-2028)

Table 48: The US Market Size of CIDP in USD Million (2017-2028)

Table 49: Market Size of CIDP by Emerging therapy in the US in USD Million (2017-2028)

Table 50: Germany Market Size of CIDP in USD Million (2017-2028)

Table 51: Market Size of CIDP by Emerging therapy in Germany in USD Million (2017-2028)

Table 52: France Market Size of CIDP in USD Million (2017-2028)

Table 53: Market Size of CIDP by Emerging therapy in France in USD Million (2017-2028)

Table 54: Italy Market Size of CIDP in USD Million (2017-2028)

Table 55: Market Size of CIDP by Emerging therapy in Italy in USD Million (2017-2028)

Table 56: Spain Market Size of CIDP in USD Million (2017-2028)

Table 57: Market Size of CIDP by Emerging therapy in Spain in USD Million (2017-2028)

Table 58: The UK Market Size of CIDP in USD Million (2017-2028)

Table 59: Market Size of CIDP by Emerging therapy in the UK in USD Million (2017-2028)

Table 60: Japan Market Size of CIDP in USD Million (2017-2028)

Table 61:Market Size of CIDP by Emerging therapy in Japan in USD Million (2017-2028)

Figure 1: Schematic presentation of distribution of demyelinating lesions and the blood-nerve barrier in (a) Typical CIDP) and (b) multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy.

Figure 2: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy

Figure 3: Algorithm of Diagnostic procedures

Figure 4: Total Prevalent Population of CIDP in the 7MM (2017-2028)

Figure 5: Total Prevalent Population of CIDP in the US (2017-2028)

Figure 6: Gender Specific Prevalence of CIDP in the US (2017-2028)

Figure 7: Clinical Subtype based Diagnosed Prevalent cases of CIDP in the United States (2017-2028)

Figure 8: Age-Specific Prevalence of CIDP in the US (2017-2028)

Figure 9: Total Prevalent Population of CIDP in Germany (2017-2028)

Figure 10: Gender Specific Prevalence of CIDP in Germany (2017-2028)

Figure 11: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Germany (2017-2028)

Figure 12: Age-Specific Prevalence of CIDP in Germany (2017-2028)

Figure 13: Total Prevalent Population of CIDP in France (2017-2028)

Figure 14: Gender Specific Prevalence of CIDP in France (2017-2028)

Figure 15: Clinical Subtype based Diagnosed Prevalent cases of CIDP in France (2017-2028)

Figure 16: Age-Specific Prevalence of CIDP in France (2017-2028)

Figure 17: Total Prevalent Population of CIDP in Italy (2017-2028)

Figure 18: Gender Specific Prevalence of CIDP in Italy (2017-2028)

Figure 19: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Italy (2017-2028)

Figure 20: Age-Specific Prevalence of CIDP in Italy (2017-2028)

Figure 21: Total Prevalent Population of CIDP in Spain (2017-2028)

Figure 22: Gender Specific Prevalence of CIDP in Spain (2017-2028)

Figure 23: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Spain (2017-2028)

Figure 24: Age-Specific Prevalence of CIDP in Spain (2017-2028)

Figure 25: Total Prevalent Population of CIDP in the UK (2017-2028)

Figure 26: Gender Specific Prevalence of CIDP in the UK (2017-2028)

Figure 27: Clinical Subtype based Diagnosed Prevalent cases of CIDP in the UK (2017-2028)

Figure 28: Age-Specific Prevalence of CIDP in the UK (2017-2028)

Figure 29: Total Prevalent Population of CIDP in Japan (2017-2028)

Figure 30: Gender Specific Prevalence of CIDP in Japan (2017-2028)

Figure 31: Clinical Subtype based Diagnosed Prevalent cases of CIDP in Japan (2017-2028)

Figure 32: Age-Specific Prevalence of CIDP in Japan (2017-2028)

Figure 33: Tretment Algorithm for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Figure 34: Unmet Needs of CIDP

Figure 35: Market Size of CIDP in the 7MM in USD Million (2017-2028)

Figure 36: Market Size of CIDP in the US, USD Millions (2017-2028)

Figure 37: Market Size of CIDP by Emerging therapy in the United States in USD Million (2017-2028)

Figure 38: Market Size of CIDP in Germany, USD Millions (2017-2028)

Figure 39: Market Size of CIDP by Emerging therapy in Germany in USD Million (2017-2028)

Figure 40: Market Size of CIDP in France, USD Millions (2017-2028)

Figure 41: Market Size of CIDP by Emerging therapy in France in USD Million (2017-2028)

Figure 42: Market Size of CIDP in Italy, USD Millions (2017-2028)

Figure 43: Market Size of by Emerging therapy in Italy in USD Million (2017-2028)

Figure 44: Market Size of of CIDP in USD Million (2017-2028)

Figure 45: Market Size of CIDP by Emerging therapy in Spain in USD Million (2017-2028)

Figure 46: Market Size of CIDP in the UK, USD Millions (2017-2028)

Figure 47: Market Size of CIDP by Emerging therapy in the UK in USD Million (2017-2028)

Figure 48: Market Size of CIDP in the Japan, USD Millions (2017-2028)

Figure 49: Market Size of CIDP by Emerging therapies in Japan in USD Million (2017-2028)

Figure 50: Market Drivers

Figure 51:Market Barriers

  • Tags:
  • Chronic Inflammatory Demyelinating...
  • Lyme disease (LD) market research
  • Lyme disease (LD) market insight
  • Lyme disease (LD) market trends
  • Lyme disease (LD) market forecast
  • Lyme disease (LD) market share
  • Lyme disease (LD) pipeline drugs
  • Lyme disease (LD) treatment algorit...
  • Lyme disease (LD) drugs
  • Lyme disease (LD) sales forecasting
  • Lyme disease (LD) market size
  • Lyme disease (LD) disease
  • Lyme disease (LD) epidemiology
  • Lyme disease (LD)
  • Lyme disease (LD) Companies
  • Lyme disease (LD) Pipeline

Forward to Friend

Need A Quote